Журнал микробиологии, эпидемиологии и иммунобиологии. 2019; : 98-105
Генетическая изменчивость Bordetella pertussis и ее роль в вакцинопрофилактике коклюша
https://doi.org/10.36233/0372-9311-2019-4-98-105Аннотация
Во многих странах мира, несмотря на высокий уровень вакцинации населения, увеличилось число вспышек коклюша во всех возрастных группах. MLST, MLVA и CGH исследования выявили несоответствие генотипов циркулирующих штаммов B.pertussis генотипам вакцинных штаммов, вследствие адаптации бактерий к вакцинированному хозяину, что привело к снижению иммунитета и возникновению вспышек заболевания коклюшем. Мутации в генах, кодирующих основные факторы вирулентности, аллельный полиморфизм и редукция генома в циркулирующих штаммах B.pertussis являются основой адаптации патогена к иммунизированной популяции и зависят от типа вакцин, используемых для иммунизации популяции. В странах, использующих бесклеточную коклюшную вакцину, доминируют в настоящее время изоляты, содержащие генотипы: ptxА1-ptxС2- ptxР3-prn2- tcfA2-1-fim3-2 и ptxА1- ptxС2- ptxР3- prnА2- tcfA2- fim2-1- fim3-1, а использующих корпускулярную вакцину, доминируют изоляты генотипов ptxА1-ptxС1- ptxР1-prn1- tcfA2- fim2-2 fim3-1 и ptxА1- ptxС1- ptxР1- prn2- tcfA2- fim2-1- fim3-1. Необходимо проведение постоянного мониторинга генотипов циркулирующих штаммов B.pertussis для своевременного выявления доминирующего генотипа и его использования в иммунизационной программе в сочетании с вакцинными штаммами B.pertussis.
Список литературы
1. Борисова О.Ю., Гадуа Н.Т., Пименова А.С., Петрова М.С., Попова О.П., Алешкин В.А., Кафарская Л.И., Донских Е.Е., Юсуф Е.В., Остапенко Н.А., Москвина Т.И., Щербакова Т.А. Структура популяции штаммов возбудителя коклюша на территории России. Эпидемиология и вакцинопрофилактика. 2016, 15(4): 22-28.
2. Еженедельный эпидемиологический бюллетень. Вакцины против коклюша: документ по позиции ВОЗ, август 2015 г., № 35. http://www.who.int/wer.
3. Каратаев Г.И., Синяшина Л.Н., Медкова А.Ю., Семин Е.Г. Персистенция бактерий Bordetella pertussis и возможный механизм ее формирования. Журн. микробиол. 2015, 6: 114-121.
4. Allen A.C., Mills K.H. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. Expert Rev. Vaccines. 2014 Oct, 13(10): 1253-1264.
5. Anselmo A., Buttinelli G., Ciammaruconi A. et al. Draft Genome Sequence of a Bordetella pertussis Strain with the Virulence-Associated Allelic Variant ptxP3, Isolated in Italy. Genome Announc. 2015 Sep 10, 3(5): е00944-15.
6. Bailon H., Leуn-Janampa N., Padilla C. et al. Increase in pertussis cases along with high prevalence of two emerging genotypes of Bordetella pertussis in Perъ, 2012. BMC Infect. Dis. 2016 Aug 17, 16: 422.
7. Belcher T., Preston A. Bordetella pertussis evolution in the (functional) genomics era. Pathog Dis. 2015 Nov, 73(8): ftv064.
8. Bottero D., Gaillard M.E., Basile L.A. et al. Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America. J. Appl. Microbiol. 2012 Jun, 112(6): 1266-12676.
9. Bouchez V., Caro V., Levillain E. et al. Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One. 2008 Jun 18, 3(6) e2437.
10. Bouchez V., Hegerle N., Strati F. et al. New Data on Vaccine Antigen Deficient Bordetella pertussis Isolates. Vaccines (Basel). 2015 Sep 14, 3(3): 751-770.
11. Bowden K.E., Weigand M.R., Peng Y. et al. Genome Structural Diversity among 31 Bordetella pertussis Isolates from Two Recent U.S. Whooping Cough Statewide Epidemics. mSphere. 2016 May 11, 1(3) pii, e00036-16.
12. Carbonetti N.H., Wirsing von Kцnig C.H., Lan R. et al. Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development. Clin. Vaccine Immunol. 2016 Nov 4, 23(11) 842-850. Print 2016 Nov.
13. Clarke M., McIntyre P.B., Blyth C.C. et al. The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis. J. Infect. 2016 Feb, 72(2) 171-178.
14. van Gent M., Heuvelman C.J., van der Heide H.G. et al. Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012. Eur. J. Clin. Microbiol. Infect. Dis. 2015 Apr, 34(4) 821-830.
15. Gorringe A.R., Vaughan T.E. Bordetella pertussis fimbriae (Fim): relevance for vaccines. Expert. Rev. Vaccines. 2014 Oct, 13(10): 1205-1214.
16. Haghighi F., Shahcheraghi F., Abbasi E. et al. Genetic Profile Variation in Vaccine Strains and Clinical Isolates of Bordetella pertussis Recovered from Iranian Patients. Avicenna J. Med. Biotechnol. 2014 Jul, 6(3): 178-184.
17. Hardwick T.H., Cassiday P., Weyant R.S. et al. Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg. Infect. Dis. 2002 Jan, 8(1): 44-49.
18. King A.J., Berbers G., van Oirschot H.F. et al. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology. 2001 Nov, 147(Pt 11): 2885-2895.
19. King A.J., van Gorkom T., Pennings J.L. et al. Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics. 2008 Jun 30, 9: 311.
20. King A.J., van Gorkom T., van der Heide H.G. et al. Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? BMC Genomics. 2010 Jan 26, 11: 64.
21. Lam C., Octavia S., Ricafort L. et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg. Infect. Dis. 2014 Apr, 20(4) 626-633.
22. Lam C., Octavia S., Sintchenko V. et al. Investigating genome reduction of Bordetella pertussis using a multiplex PCR-based reverse line blot assay (mPCR/RLB). BMC Res. Notes. 2014 Oct 15, 7: 727.
23. Hijnen M., Mooi F.R., van Gageldonk P.G. et al. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect. Immun. 2004 Jul, 72(7): 3716-3723.
24. de Melker H.E., Conyn-van Spaendonck M.A., Rümke H.C. et al. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg. Infect. Dis. 1997 Apr-Jun, 3(2): 175-178.
25. de Melker H.E., Schellekens J.F., Neppelenbroek S.E. et al. Reemergence of pertussis in the haghly vaccinated population of the Netherlands:observations on survellance date. Emerg. Infect. Dis. 2000 Jul-Aug, 6(4): 348-357.
26. Miyaji Y., Otsuka N., Toyoizumi-Ajisaka H. et al. Genetic analysis of Bordetella pertussis isolates from the 2008-2010 pertussis epidemic in Japan. PLoS One. 2013 Oct 4, 8(10): e77165.
27. Mosiej E., Krysztopa-Grzybowska K., Polak M. et al. Multi-locus variable-number tandem repeat analysis of Bordetella pertussis isolates сirculating in Pоland in the period 1959-2013. Med. Microbiol. 2017 Jun, 66(6): 753-761.
28. Petersen R.F., Dalby T., Dragsted D.M. et al. Temporal trends in Bordetella pertussis populations, Denmark, 1949-2010. Emerg. Infect. Dis. 2012 May, 18(5): 767-74.
29. Poynten M., McIntyre P.B., Mooi F.R. et al. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol. Infect. 2004 Apr, 132(2): 185-193.
30. Sealey K.L., Harris S.R., Fry N.K. et al. Genomic analysis of isolates from the United Kingdom 2012 pertussis outbreak reveals that vaccine antigen genes are unusually fast evolving. J. Infect. Dis. 2015 Jul 15, 212(2): 294-301.
31. Sealey K.L., Belcher T., Preston A. Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence. Infect. Genet. Evol. 2016 Jun, 406:136-143
32. Sedighi I., Karimi A., Amanati A. Old Disease and New Challenges: Major Obstacles of Current Strategies in the Prevention of Pertussis. Iran. J. Pediatr. 2016 Jun 12, 26(4): e5514.
33. Shuel M., Lefebvre B., Whyte K. et al. Antigenic and genetic characterization of Bordetella pertussis recovered from Quebec, Canada, 2002-2014: detection of a genetic shift. Can. J. Microbiol. 2016 May, 62(5):437-441.
34. Sönmez C., Cöplü N., Gözalan A. et al. Serological evaluation of Bordetella pertussis infection in adults with prolonged cough. Miсrobiyol. Bul. 2016 Jul, 50(3): 361-370.
35. Vaughan T.E., Pratt C.B., Sealey K. et al. Plasticity of fimbrial genotype and serotype within populations of Bordetella pertussis: analysis by paired flow cytometry and genome sequencing. Microbiology. 2014 Sep, 160(Pt 9): 2030-2044.
36. Wagner B., Melzer H., Freymüller G. et al. Genetic Variation of Bordetella pertussis in Austria. PLoS One. 2015 Jul 16,10(7): e0132623.
37. Weber C., Boursaux-Eude C., Coralie G. et al. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J. Clin. Microbiol. 2001 Dec, 39(12): 4396-4440.
38. Xu Y., Liu B. et al. Whole-genome sequencing reveals the effect of vaccination on the evolution of Bordetella pertussis. Sci. Rep. 2015 Aug 18, 5: 12888.
Journal of microbiology, epidemiology and immunobiology. 2019; : 98-105
Genetic variability of Bordetella pertussis and its role in vaccine prevention of pertussis
https://doi.org/10.36233/0372-9311-2019-4-98-105Abstract
In many countries of the world despite the extensively vaccination against pertussis has increased the incidence of the whooping cough in all age group of the population. The MLST, MLVA and CGH investigations revealed the differences in genotypes between the vaccine strains B.pertussis and the circulating isolates B.pertussis in consequence of adaptation of the bacterium B.pertussis to the immunized hosts. It is lead to waning immynity and outbreak of incidence of pertussis. The mutations in the genes encoding the major virulence factors, the allelic polimorfism and decreasing the genome size of B.pertussis strains are the basis of the B.pertussis adaptation to the immunized hosts and dependent on the type of the vaccine used for immunization Programme. In countries that use acellular pertussis vaccine for vaccination programme the dominant isolates genotypes are: ptxА1-ptxС2- ptxР3-prn2- tcfA2-1-fim3-2 и ptxА1- ptxС2- ptxР3-prnА2- tcfA2- fim2-1- fim3-1, and that use the cellular pertussis vaccine the dominant isolates genotypes are ptxА1-ptxС1- ptxР1-prn1- tcfA2- fim2-2 fim3-1 и ptxА1- ptxС1- ptxР1- prn2- tcfA2- fim2-1- fim3-1. The constant monitoring of the genotypes of isolates B.pertussis is necessary to reveal the dominant genotypes and include them in the national immunization programme in combination with vaccine strains B.pertussis.
References
1. Borisova O.Yu., Gadua N.T., Pimenova A.S., Petrova M.S., Popova O.P., Aleshkin V.A., Kafarskaya L.I., Donskikh E.E., Yusuf E.V., Ostapenko N.A., Moskvina T.I., Shcherbakova T.A. Struktura populyatsii shtammov vozbuditelya koklyusha na territorii Rossii. Epidemiologiya i vaktsinoprofilaktika. 2016, 15(4): 22-28.
2. Ezhenedel'nyi epidemiologicheskii byulleten'. Vaktsiny protiv koklyusha: dokument po pozitsii VOZ, avgust 2015 g., № 35. http://www.who.int/wer.
3. Karataev G.I., Sinyashina L.N., Medkova A.Yu., Semin E.G. Persistentsiya bakterii Bordetella pertussis i vozmozhnyi mekhanizm ee formirovaniya. Zhurn. mikrobiol. 2015, 6: 114-121.
4. Allen A.C., Mills K.H. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. Expert Rev. Vaccines. 2014 Oct, 13(10): 1253-1264.
5. Anselmo A., Buttinelli G., Ciammaruconi A. et al. Draft Genome Sequence of a Bordetella pertussis Strain with the Virulence-Associated Allelic Variant ptxP3, Isolated in Italy. Genome Announc. 2015 Sep 10, 3(5): e00944-15.
6. Bailon H., Leun-Janampa N., Padilla C. et al. Increase in pertussis cases along with high prevalence of two emerging genotypes of Bordetella pertussis in Per\", 2012. BMC Infect. Dis. 2016 Aug 17, 16: 422.
7. Belcher T., Preston A. Bordetella pertussis evolution in the (functional) genomics era. Pathog Dis. 2015 Nov, 73(8): ftv064.
8. Bottero D., Gaillard M.E., Basile L.A. et al. Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America. J. Appl. Microbiol. 2012 Jun, 112(6): 1266-12676.
9. Bouchez V., Caro V., Levillain E. et al. Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS One. 2008 Jun 18, 3(6) e2437.
10. Bouchez V., Hegerle N., Strati F. et al. New Data on Vaccine Antigen Deficient Bordetella pertussis Isolates. Vaccines (Basel). 2015 Sep 14, 3(3): 751-770.
11. Bowden K.E., Weigand M.R., Peng Y. et al. Genome Structural Diversity among 31 Bordetella pertussis Isolates from Two Recent U.S. Whooping Cough Statewide Epidemics. mSphere. 2016 May 11, 1(3) pii, e00036-16.
12. Carbonetti N.H., Wirsing von Ktsnig C.H., Lan R. et al. Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development. Clin. Vaccine Immunol. 2016 Nov 4, 23(11) 842-850. Print 2016 Nov.
13. Clarke M., McIntyre P.B., Blyth C.C. et al. The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis. J. Infect. 2016 Feb, 72(2) 171-178.
14. van Gent M., Heuvelman C.J., van der Heide H.G. et al. Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012. Eur. J. Clin. Microbiol. Infect. Dis. 2015 Apr, 34(4) 821-830.
15. Gorringe A.R., Vaughan T.E. Bordetella pertussis fimbriae (Fim): relevance for vaccines. Expert. Rev. Vaccines. 2014 Oct, 13(10): 1205-1214.
16. Haghighi F., Shahcheraghi F., Abbasi E. et al. Genetic Profile Variation in Vaccine Strains and Clinical Isolates of Bordetella pertussis Recovered from Iranian Patients. Avicenna J. Med. Biotechnol. 2014 Jul, 6(3): 178-184.
17. Hardwick T.H., Cassiday P., Weyant R.S. et al. Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg. Infect. Dis. 2002 Jan, 8(1): 44-49.
18. King A.J., Berbers G., van Oirschot H.F. et al. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology. 2001 Nov, 147(Pt 11): 2885-2895.
19. King A.J., van Gorkom T., Pennings J.L. et al. Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics. 2008 Jun 30, 9: 311.
20. King A.J., van Gorkom T., van der Heide H.G. et al. Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? BMC Genomics. 2010 Jan 26, 11: 64.
21. Lam C., Octavia S., Ricafort L. et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg. Infect. Dis. 2014 Apr, 20(4) 626-633.
22. Lam C., Octavia S., Sintchenko V. et al. Investigating genome reduction of Bordetella pertussis using a multiplex PCR-based reverse line blot assay (mPCR/RLB). BMC Res. Notes. 2014 Oct 15, 7: 727.
23. Hijnen M., Mooi F.R., van Gageldonk P.G. et al. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect. Immun. 2004 Jul, 72(7): 3716-3723.
24. de Melker H.E., Conyn-van Spaendonck M.A., Rümke H.C. et al. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg. Infect. Dis. 1997 Apr-Jun, 3(2): 175-178.
25. de Melker H.E., Schellekens J.F., Neppelenbroek S.E. et al. Reemergence of pertussis in the haghly vaccinated population of the Netherlands:observations on survellance date. Emerg. Infect. Dis. 2000 Jul-Aug, 6(4): 348-357.
26. Miyaji Y., Otsuka N., Toyoizumi-Ajisaka H. et al. Genetic analysis of Bordetella pertussis isolates from the 2008-2010 pertussis epidemic in Japan. PLoS One. 2013 Oct 4, 8(10): e77165.
27. Mosiej E., Krysztopa-Grzybowska K., Polak M. et al. Multi-locus variable-number tandem repeat analysis of Bordetella pertussis isolates sirculating in Poland in the period 1959-2013. Med. Microbiol. 2017 Jun, 66(6): 753-761.
28. Petersen R.F., Dalby T., Dragsted D.M. et al. Temporal trends in Bordetella pertussis populations, Denmark, 1949-2010. Emerg. Infect. Dis. 2012 May, 18(5): 767-74.
29. Poynten M., McIntyre P.B., Mooi F.R. et al. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol. Infect. 2004 Apr, 132(2): 185-193.
30. Sealey K.L., Harris S.R., Fry N.K. et al. Genomic analysis of isolates from the United Kingdom 2012 pertussis outbreak reveals that vaccine antigen genes are unusually fast evolving. J. Infect. Dis. 2015 Jul 15, 212(2): 294-301.
31. Sealey K.L., Belcher T., Preston A. Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence. Infect. Genet. Evol. 2016 Jun, 406:136-143
32. Sedighi I., Karimi A., Amanati A. Old Disease and New Challenges: Major Obstacles of Current Strategies in the Prevention of Pertussis. Iran. J. Pediatr. 2016 Jun 12, 26(4): e5514.
33. Shuel M., Lefebvre B., Whyte K. et al. Antigenic and genetic characterization of Bordetella pertussis recovered from Quebec, Canada, 2002-2014: detection of a genetic shift. Can. J. Microbiol. 2016 May, 62(5):437-441.
34. Sönmez C., Cöplü N., Gözalan A. et al. Serological evaluation of Bordetella pertussis infection in adults with prolonged cough. Misrobiyol. Bul. 2016 Jul, 50(3): 361-370.
35. Vaughan T.E., Pratt C.B., Sealey K. et al. Plasticity of fimbrial genotype and serotype within populations of Bordetella pertussis: analysis by paired flow cytometry and genome sequencing. Microbiology. 2014 Sep, 160(Pt 9): 2030-2044.
36. Wagner B., Melzer H., Freymüller G. et al. Genetic Variation of Bordetella pertussis in Austria. PLoS One. 2015 Jul 16,10(7): e0132623.
37. Weber C., Boursaux-Eude C., Coralie G. et al. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J. Clin. Microbiol. 2001 Dec, 39(12): 4396-4440.
38. Xu Y., Liu B. et al. Whole-genome sequencing reveals the effect of vaccination on the evolution of Bordetella pertussis. Sci. Rep. 2015 Aug 18, 5: 12888.
